Idebenone
Contents
Description
Idebenone is a synthetic analog of coenzyme Q10 with antioxidant properties. It is approved in the European Union for the treatment of visual impairment in adolescent and adult patients with Leber's hereditary optic neuropathy (LHON). The drug has also been investigated for other mitochondrial and neurodegenerative conditions including certain forms of muscular dystrophy.
Indications & Therapeutic Use
Leber hereditary optic neuropathy, investigational: Duchenne muscular dystrophy, Friedreich ataxia
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Idebenone — GNH India
10 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | idebenone |
| Brands | 1 brand available |
| Active Ingredient | idebenone |
| Drug Class | Leber hereditary optic neuropathy |
| Manufacturer | Santhera Pharmaceuticals |
| Dosage Forms | oral tablet, 150 mg |
| Medical Code | N06BX13 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 21 days |
| Reg. Status | EMA Approved |
| Clinical Trial | NCT02774005 |
| Countries | 9 countries |